RVO
HomeMarketplace
Register
Register
Register

ServiceUpdated on 15 July 2025

mass spectrometry

Monique van Scherpenzeel

CEO and founder at GlycoMScan B.V.

Arnhem, Netherlands

About

With a unique background as PhD in Pharmacy and Chemistry, we have a broad knowledge in the analysis of molecules in complex biological matrices, ranging from small organic molecules to large proteins such as therapeutic antibodies.

Our expertise is the analysis of protein glycosylation and the building blocks thereof, which are nucleotide sugars.

Applies to

  • Innovative therapies - Gene therapy
  • Innovative therapies - Immune cell therapy
  • Innovative therapies - RNA therapy
  • Innovative therapies - Nanomedicine
  • Innovative therapies - Precision medicine
  • Innovative human-based test models - 2D & 3D in vitro cell culture models
  • Innovative human-based test models - 3D spheroids
  • Innovative human-based test models - 3D spheroids
  • Innovative human-based test models - Organ-on-Chip
  • Innovative human-based test models - Assembloids and multi-tissue models
  • Innovative human-based test models - Bioprinted tissues and constructs
  • Innovative human-based test models - In silico human models
  • Development stages and support fuctions - Early discovery / basic research
  • Development stages and support fuctions - Technology development and validation
  • Development stages and support fuctions - Pre-clinical research and development
  • Development stages and support fuctions - Contract research (CRO / CRMO)

Organisation

GlycoMScan B.V.

Company

Snelliusweg 75, 6827DG Arnhem, Netherlands

Similar opportunities

  • Product

    EDDI - Epigenetic Digital Data Interface

    • Innovative therapies - RNA therapy
    • Innovative therapies - Gene therapy
    • Innovative therapies - Gene editing
    • Innovative therapies - Nanomedicine
    • Innovative therapies - Stem cell therapy
    • Innovative therapies - Oncolytic viruses
    • Innovative therapies - Microbiome therapy
    • Innovative therapies - Precision medicine
    • Innovative therapies - Immune cell therapy
    • Innovative therapies - Somatic cell therapy
    • Innovative therapies - Tissue engineered products
    • Innovative human-based test models - 3D spheroids
    • Innovative human-based test models - 3D spheroids
    • Innovative human-based test models - Organ-on-Chip
    • Innovative human-based test models - In silico human models
    • Development stages and support fuctions - Regulatory and compliance
    • Innovative human-based test models - Bioprinted tissues and constructs
    • Development stages and support fuctions - Data management and analytics
    • Innovative human-based test models - Assembloids and multi-tissue models
    • Development stages and support fuctions - Contract research (CRO / CRMO)
    • Innovative human-based test models - 2D & 3D in vitro cell culture models
    • Development stages and support fuctions - Early discovery / basic research
    • Development stages and support fuctions - Funding, capital and investments
    • Development stages and support fuctions - Ethics and social responsibility
    • Development stages and support fuctions - Clinical research and development
    • Development stages and support fuctions - Development and (GMP) manufacturing
    • Development stages and support fuctions - Technology development and validation
    • Development stages and support fuctions - Pre-clinical research and development
    • Development stages and support fuctions - Commercial strategy and market access

    daniel lüscher

    CEO at QBDC GmbH

    Nusshof, Switzerland

  • Service

    SynergyFinder

    • Consulting
    • Development
    • Innovative therapies - Nanomedicine
    • Innovative therapies - Precision medicine
    • Innovative therapies - Immune cell therapy
    • Innovative human-based test models - 3D spheroids
    • Innovative human-based test models - 2D & 3D in vitro cell culture models
    • Development stages and support fuctions - Clinical research and development
    • Development stages and support fuctions - Pre-clinical research and development

    Guido Zaman

    Managing Director at Oncolines B.V.

    Oss, Netherlands

  • Service

    Oncolines cancer cell panel profiling

    • Consulting
    • Development
    • Innovative therapies - Precision medicine
    • Innovative therapies - Immune cell therapy
    • Innovative human-based test models - 3D spheroids
    • Innovative human-based test models - 2D & 3D in vitro cell culture models
    • Development stages and support fuctions - Clinical research and development
    • Development stages and support fuctions - Pre-clinical research and development

    Guido Zaman

    Managing Director at Oncolines B.V.

    Oss, Netherlands